US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Oxcarbazepine Oral Suspension

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0834-2023
Class II · Moderate risk Ongoing

Olopatadine HCl Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0833-2023
Class II · Moderate risk Ongoing

Olopatadine HCl Nasal Spray

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0832-2023
Class II · Moderate risk Ongoing

Neomycin & Polymyxin B Sulfates

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0831-2023
Class II · Moderate risk Ongoing

Naloxone Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0830-2023
Class II · Moderate risk Ongoing

Moxifloxacin HCl Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0829-2023
Class II · Moderate risk Ongoing

Midazolam Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0828-2023
Class II · Moderate risk Ongoing

Megestrol Acetate Oral Suspension

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0827-2023
Class II · Moderate risk Ongoing

Lorazepam Oral Concentrate

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0826-2023
Class II · Moderate risk Ongoing

Lorazepam Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0825-2023
Class II · Moderate risk Ongoing

Lidocaine HCl Jelly USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0823-2023
Class II · Moderate risk Ongoing

Lidocaine Ointment USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0822-2023
Class II · Moderate risk Ongoing

Lidocaine 2.5% & Prilocaine 2.5% Cream

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0821-2023
Class II · Moderate risk Ongoing

Levofloxacin Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0820-2023
Class II · Moderate risk Ongoing

Levofloxacin Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0819-2023
Class II · Moderate risk Ongoing

Levofloxacin Injection 500mg/20 mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0818-2023
Class II · Moderate risk Ongoing

Levocarnitine Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0817-2023
Class II · Moderate risk Ongoing

Levetiracetam Oral Solution 100 mg/mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0816-2023
Class II · Moderate risk Ongoing

Lactulose Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0815-2023
Class II · Moderate risk Ongoing

Lactulose Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0814-2023
Class II · Moderate risk Ongoing

Ketorolac Tromethamine Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0813-2023
Class II · Moderate risk Ongoing

IC-Green

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0812-2023
Class II · Moderate risk Ongoing

Hydromorphone Hydrochloride Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0811-2023